We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Near-Patient Sepsis Triage Test Provides Results in 20 Minutes

By LabMedica International staff writers
Posted on 08 Jul 2022

Interleukin-6 (IL-6), an established biomarker of immune system activation, is elevated in infection, inflammation, and cancer, and presents as an early “first responder” that needs to be measured quickly and reliably. More...

Now, a new test for sepsis triage that measures IL-6 is designed to provide accurate, reliable results in approximately 20 minutes from ‘sample-to-result’ and help medical professionals make earlier and better triage/treatment decisions.

Bluejay Diagnostics, Inc.’s (Acton, MA, USA) is developing the Symphony IL-6 Test to rapidly measure IL-6 in whole blood in a near-patient setting that is intended to help healthcare professionals make better treatment decisions for patients with life threatening diseases. The Symphony IL-6 Test is designed to run on Bluejay’s Symphony System that is intended to address the need for simple, reliable, rapid near-patient testing. The Symphony System is based on a well-accepted test method (ELISA, Enzyme-Linked Immunosorbent Assay) using advances in nanotechnology and new approaches to microfluidics.

The Symphony System is designed to provide quantitative measurements of specific biomarkers to determine the need for additional patient care and monitoring, when used in combination with other test and laboratory measurements. The system does not require any sample prep and has been shown in published clinical studies to deliver results in about 24 minutes. This user-friendly system is expected to fit into ICU/near-patient settings without the need for dedicated staff to run a test. The system has been designed to measure test analytes using whole blood. Samples are collected and loaded into proprietary, test-specific cartridges. Bluejay has completed the planned clinical studies for the Symphony IL-6 Test which is currently a development stage product candidate.

“Efficient measurement of clinically relevant biomarkers in critical care settings may help medical professionals make more timely and effective treatment decisions,” said Neil Dey, Chief Executive Officer of Bluejay Diagnostics, Inc. “With the progress made in our clinical program for the Symphony IL-6 Test, we are closer to executing our mission of providing first-in-class, near-patient, laboratory quality tests using whole blood.”

Related Links:
Bluejay Diagnostics, Inc. 


New
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
Online QC Software
Acusera 24•7
Urine Analyzer
respons® UDS100
Prefilled Tubes
Prefilled 5.0ml Tubes
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Fully Automated Test Advances Hepatitis D Diagnosis and Monitoring

Hepatitis D virus infection can accelerate progression to cirrhosis and liver cancer, making timely diagnosis and longitudinal monitoring essential. Because hepatitis D depends on co-infection or superinfection... Read more

Hematology

view channel
Image Credit: Shutterstock

New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more

Immunology

view channel
Image:Proteomic tear-fluid analysis revealed abnormal patterns in proteins that regulate nerves and T cells in individuals with eye problems (Image Credit: Adobe Stock)

Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19

Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more

Industry

view channel
Photo courtesy of Natera

Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing

Natera’s Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR), becoming the first personalized MRD test for solid tumors to achieve... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.